“牛皮袋装百元现钞给医生回扣”，国家医保局曝光医药贿赂案细节，基金监管“零容忍”

Core Viewpoint - The National Medical Insurance Administration (NMIA) has intensified its oversight of the entire illegal profit chain involving medical insurance, covering participants from insured individuals to medical institutions, pharmaceutical representatives, drug dealers, and pharmacies, signaling a zero-tolerance approach towards medical corruption and a commitment to safeguarding medical insurance funds [1][7]. Group 1: Recent Cases and Legal Actions - The NMIA has publicly disclosed multiple cases of bribery and fraud in the medical procurement sector, including significant financial details such as a total of 1.6363 million yuan in kickbacks paid by Huang to 15 doctors and 14.0333 million yuan in bribes from a trading company to doctors at a hospital [2][3]. - A case involving Liu, a pharmacy director, revealed that he accepted a total of 1.1624 million yuan in bribes from various agents, highlighting the extent of corruption within the procurement process [3]. - The NMIA's actions reflect a judicial stance of severe punishment for medical corruption, emphasizing that even in cases of self-reporting or restitution, offenders will face strict penalties [3][7]. Group 2: Regulatory Measures and Future Directions - The NMIA established a credit evaluation system for pricing and procurement in 2020, which includes penalties for companies involved in bribery and unethical sales practices, aiming to enhance the integrity of the medical insurance system [4]. - The NMIA is set to guide local insurance bureaus in implementing credit ratings and enforcing corrective measures for companies that have engaged in dishonest practices, thereby better protecting medical insurance funds [4]. - The regulatory focus has shifted from reactive measures to proactive prevention, utilizing intelligent monitoring systems and a comprehensive evaluation framework to ensure long-term accountability in the medical sector [7].